Patent Assignment
Reel/Frame 072360/0140
Assignment of Assignor's Interest
Recorded: 2025-08-21
Pages: 9
Assignor
TABUTEAU, HERRIOT
Executed: 2025-08-19
Assignee
AXSOME THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NEW YORK, 10007
Covered Properties
(39)
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/753,357 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/756,469 →
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/761,478 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/762,305 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/763,050 →
Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions
Application:
19/065,198 →
Publication:
US US20250195465A1
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/074,873 →
Publication:
US US20260216200A1
Methods of Treating Migraines with a Combination of a Meloxicam and a Rizatriptan
Patent:
12,544,383 →
Application:
19/075,007 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/770,501 →
Use of Mazindol to Treat Nervous System Disorders
Application:
19/077,364 →
Publication:
US US20250360107A1
Dosage Forms Containing Esreboxetine Having Improved Purity
Application:
19/083,348 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/085,084 →
Publication:
US US20260027127A1
(S)-2-((S)-(2-Ethoxyphenoxy)(Phenyl)Methyl)-4-Nitrosomorpholine
Patent:
12,565,478 →
Application:
19/096,247 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/169,261 →
Publication:
US US20250255880A1
Pharmaceutical Compositions Comprising Uniform Blends of Esreboxetine
Application:
19/172,485 →
Publication:
US US20260207613A1
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/181,172 →
Publication:
US US20260000677A1
Combination Dosage Forms and Administration Thereof
Application:
19/195,620 →
Publication:
US US20250387349A1
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/196,655 →
Publication:
US US20260069603A1
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Treatment of Narcolepsy with Reboxetine
Application:
63/816,529 →
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Pharmaceutical Compositions Comprising Meloxicam
Application:
63/822,108 →
Pharmaceutical Compositions Comprising Meloxicam
Application:
19/236,838 →
Publication:
US US20250302844A1
Pharmaceutical Compositions Comprising Bupropion and Cysteine
Pharmaceutical Compositions Comprising Meloxicam
Dosage Forms Comprising Active Pharmaceutical Ingredients
Application:
19/266,899 →
Publication:
US US20250367121A1
Pharmaceutical Compositions Comprising Bupropion and Cysteine
Application:
19/270,315 →
Publication:
US US20250339538A1
Use of Reboxetine to Treat Narcolepsy
Application:
63/848,145 →
Dosage Forms Containing Reboxetine Having Improved Purity
Application:
63/848,890 →
Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion
Application:
19/278,685 →
Publication:
US US20260014142A1
Use of Esreboxetine to Treat Nervous System Disorders Such as Fibromyalgia
Application:
19/278,727 →
Publication:
US US20260014165A1
Use of Reboxetine to Treat Narcolepsy
PCT:
PCT/US2025/021386 ↗
Pharmaceutical Compositions Comprising Meloxicam
PCT:
PCT/US2025/023660 ↗
Related Assignments
(1)
Other recorded transfers of the patents in this record — the chain of ownership.